TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Cells Année : 2021

TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis

Résumé

Cystic fibrosis (CF) is the most common of rare hereditary diseases in Caucasians, and it is estimated to affect 75,000 patients globally. CF is a complex disease due to the multiplicity of mutations found in the CF transmembrane conductance regulator (CFTR) gene causing the CFTR protein to become dysfunctional. Correctors and potentiators have demonstrated good clinical outcomes for patients with specific gene mutations; however, there are still patients for whom those treatments are not suitable and require alternative CFTR-independent strategies. Although CFTR is the main chloride channel in the lungs, others could, e.g., anoctamin-1 (ANO1 or TMEM16A), compensate for the deficiency of CFTR. This review summarizes the current knowledge on calcium-activated chloride channel (CaCC) ANO1 and presents ANO1 as an exciting target in CF.
Fichier principal
Vignette du fichier
cells-10-02867.pdf (1.3 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03456553 , version 1 (30-11-2021)

Identifiants

Citer

Christie Mitri, Himanshu Sharma, Harriet Corvol, Olivier Tabary. TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis. Cells, 2021, 10 (11), pp.2867. ⟨10.3390/cells10112867⟩. ⟨hal-03456553⟩
42 Consultations
59 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More